Company Description

G1, a Pharmacosmos Therapeutics subsidiary, is a commercial-stage biopharmaceutical company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA (trilaciclib).